Optimizing Outcomes in Hypoparathyroidism: A New Era in Treatment Approaches - Episode 12
Emerging Therapies in Hypoparathyroidism
In ‘Emerging Therapies in Hypoparathyroidism,’ our experts delve into three emerging therapies in chronic hypoparathyroidism.
In ‘Emerging Therapies in Hypoparathyroidism,’ our experts delve into three emerging therapies in chronic hypoparathyroidism.
Led by the moderator, Dr. Kohlmeier, the expert endocrinologists, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, examine the following critical questions:
- What are your impressions of emerging therapies, such as eneboparatide (a PTH1R agonist), encaleret (a calcilytic agent), and MBX 2109 (PTH peptide prodrug) for their potential to manage chronic hypoparathyroidism?
The panel evaluates eneboparatide, a PTH1R agonist that closely mimics native parathyroid hormone signaling; MBX 2109, a PTH peptide prodrug engineered for sustained, physiologic PTH exposure; and encaleret, a calcilytic that modulates the calcium‑sensing receptor to enhance endogenous PTH release. Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.
Our next episode, ‘Closing Thoughts on Hypoparathyroidism Management,’ wraps up the series with the panelists’ final thoughts on the management of hypoparathyroidism.
